Market capitalization | $3.14b |
Enterprise Value | $3.00b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 19.17 |
P/S ratio (TTM) P/S ratio | 20.10 |
P/B ratio (TTM) P/B ratio | 11.89 |
Sales growth (TTM) Sales growth | 83.44% |
Turnover (TTM) Turnover | $156.33m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
9 Analysts have issued a PROCEPT BioRobotics forecast:
9 Analysts have issued a PROCEPT BioRobotics forecast:
Mar '24 |
+/-
%
|
||
Turnover | 156 156 |
83%
83%
|
|
Gross income | 80 80 |
107%
107%
|
|
EBITDA | -104 -104 |
18%
18%
|
EBIT (operating result) EBIT | -108 -108 |
16%
16%
|
Net profit | -103 -103 |
5%
5%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Reza Zadno |
Employees | 626 |
Founded | 2007 |
Website | www.procept-biorobotics.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.